Project description
Proprietary dressings for the treatment of chronic wounds
Treatment of non-healing chronic wounds represents an unmet clinical need with conventional wound dressings failing to protect against recurrent infections, leading to increased mortality. The rising incidence of diabetes and obesity alongside antibiotic resistance exacerbate the situation. The EU-funded WHILYAS-2 project proposes to address the insufficient treatment of chronic wounds through a proprietary technology that utilises chemokines as therapeutic agents through local administration from genetically modified lactic acid bacteria. For clinical proof of concept, partners will conduct a phase II clinical trial of their drug candidate ILP100 Topical in patients with diabetes.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health scienceshealth sciencespublic healthepidemiologypandemics
- medical and health sciencesclinical medicineendocrinologydiabetes
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Programme(s)
Call for proposal
H2020-EIC-SMEInst-2018-2020-3
See other projects for this call
Funding Scheme
SME-2b - SME Instrument (grant only and blended finance)
Coordinator
752 37 Uppsala
Sweden
See on map